ADAR2 deficiency ameliorates non‐alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1.

MLA

Kung, Mei‐Lang, et al. “ADAR2 Deficiency Ameliorates Non‐alcoholic Fatty Liver Disease and Muscle Atrophy through Modulating Serum Amyloid A1.” Journal of Cachexia, Sarcopenia & Muscle, vol. 15, no. 3, June 2024, pp. 949–62. EBSCOhost, https://doi.org/10.1002/jcsm.13460.

APA

Kung, M., Yang, T., Lin, C., Ho, J., Hung, T., Chang, C., Huang, K., Chen, C., & Chen, Y. (2024). ADAR2 deficiency ameliorates non‐alcoholic fatty liver disease and muscle atrophy through modulating serum amyloid A1. Journal of Cachexia, Sarcopenia & Muscle, 15(3), 949–962. https://doi.org/10.1002/jcsm.13460

Chicago

Kung, Mei‐Lang, Tai‐Hua Yang, Chia‐Chi Lin, Jia‐Yun Ho, Tzu‐Chi Hung, Chih‐Hsiang Chang, Kuan‐Wen Huang, Chien‐Chin Chen, and Yun‐Wen Chen. 2024. “ADAR2 Deficiency Ameliorates Non‐alcoholic Fatty Liver Disease and Muscle Atrophy through Modulating Serum Amyloid A1.” Journal of Cachexia, Sarcopenia & Muscle 15 (3): 949–62. doi:10.1002/jcsm.13460.